Mersana To Focus Fully On Anti-Cancer ADCs With $27M Recapitalization
This article was originally published in The Pink Sheet Daily
Nearly ready to out-license its remaining small molecule drug conjugate candidate, Mersana will focus exclusively on developing Fleximer-based antibody-drug conjugates through collaborations with Endo and future partners.
You may also be interested in...
Previously partnered with Teva on a small molecule drug conjugate, biotech says its focus going forward will be on developing ADCs, with partners and in-house.